drugset / Trial / NCT05648006
First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, multicenter, open, randomized controlled Phase II clinical study to evaluate the efficacy and safety of intratumoral injection of OH2 combined with capecitabine for first-line maintenance of advanced colorectal cancer.
Timeline
- Start
- 2023-10-17
- Primary completion
- 2024-04-15
- Completion
- 2024-04-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | OH2 | Other / unclassified | 1e+07 unknown | Intramuscular |
| Background | Capecitabine | Small molecule | 1000 mg/m2 | Oral |